biopharma-reporter2d
Sarepta discontinues development of Duchenne ASO treatment vesleteplirsen
The US biopharma will discontinue development of the Exondys 51 (eteplirsen) follow up treatment to focus on other treatment ...
biopharma-reporter2d
Aditum Bio and Leads Biolabs join forces in new company to fight autoimmune diseases
The U.S. company Aditum Bio and Chinese company Leads Biolabs today announced that they have founded Oblenio Bio, a new ...
biopharma-reporter4d
EMA accepts Alvotech and Advanz Pharma’s Marketing Authorization Application for biosimilar of J&J’s Simponi
The Simponi biosimilar, AVT05, has shown positive top-line results in patients with moderate to severe rheumatoid arthritis.
biopharma-reporter4d
Synaffix and BigHat Biosciences collaborate to develop AI-designed ADC
The Dutch biotech Synaffix and the Swiss company BigHat Biosciences announced yesterday that they have entered into a ...
biopharma-reporter8d
Top 10 rare disease pharma sees 10.4% rise in therapy start
A new case study released by AllazoHealth reveals that a leading rare disease pharmaceutical company achieved a 10.4% ...
biopharma-reporter8d
Abzena’s advanced drug development showcased at CPHI Milan
At CPHI Milan 2024, Abzena showcased its latest innovations in cell line development and ADC manufacturing, featuring the ...
biopharma-reporter8d
All news articles for November 2024
The US biopharma will discontinue development of the Exondys 51 (eteplirsen) follow up treatment to focus on other treatment candidates.
biopharma-reporter9d
Abzena announces major expansion of its biologics manufacturing facility
The U.S. contract development and manufacturing organization (CDMO) Abzena announced yesterday that it has significantly ...